GlassScriptPhysician profile
Shannon K Twiddy
NPI 1386899292
$3,990.20
in general payments reported to CMS, 2019-2025
41 companies · $754 in 2025
The $754 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $69.40 · 2021: $518 · 2022: $887 · 2023: $779 · 2024: $593 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,126.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625.96 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $580.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $348.77 | 2020-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $213.07 | 2019-2025 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Lilly USA, LLC | $201.15 | 2021-2025 | Jardiance, Emgality, Zepbound |
| Amgen INC. | $198.51 | 2019-2024 | Prolia, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.55 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $179.91 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $173.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $143.85 | 2019-2024 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $123.07 | 2022-2025 | |
| Corium, LLC | $103.39 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.83 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $73.22 | 2019-2022 | |
| Dexcom, INC. | $59.06 | 2023-2025 | Dexcom G6 Transmitter |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Twiddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.